Skip to main content
British Medical Journal logoLink to British Medical Journal
. 1976 Apr 10;1(6014):864–867. doi: 10.1136/bmj.1.6014.864

Treatment of overt meningeal leukaemia in children: results of second MRC meningeal leukaemia trial.

M L Willoughby
PMCID: PMC1639530  PMID: 816410

Abstract

After induction ofmeningeal remission by a course of intrathecal methotrexate patients were randomly allocated to receive either cranial irradiation or craniospinal irradiation. Patients being treated for their first meningeal relapse were randomised separately from those in their second or subsequent relapse. All eight patients in their first relapse who were given cranial irradiation alone developed further meningeal recurrence (median length of remission 15 weeks) compared with only two out of nine given craniospinal irradiation (median length of remission at least 99 weeks). Four of the nine patients given craniospinal irradiation were alive and without further meningeal relapse two and a half to four years after treatment. Craniospinal irradiation produced no such advantage for patients entering the trial in their second or subsequent meningeal relapse.

Full text

PDF
866

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Duttera M. J., Bleyer W. A., Pomeroy T. C., Leventhal C. M., Leventhal B. G. Irradiation, methotrexate toxicity, and the treatment of meningeal leukaemia. Lancet. 1973 Sep 29;2(7831):703–707. doi: 10.1016/s0140-6736(73)92539-7. [DOI] [PubMed] [Google Scholar]
  2. Hustu H. O., Aur R. J., Verzosa M. S., Simone J. V., Pinkel D. Prevention of central nervous system leukemia by irradiation. Cancer. 1973 Sep;32(3):585–597. doi: 10.1002/1097-0142(197309)32:3<585::aid-cncr2820320311>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  3. Kay H. E., Knapton P. J., O'Sullivan J. P., Wells D. G., Harris R. F., Innes E. M., Stuart J., Schwartz F. C., Thompson E. N. Encephalopathy in acute leukaemia associated with methotrexate therapy. Arch Dis Child. 1972 Jun;47(253):344–354. doi: 10.1136/adc.47.253.344. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Price R. A., Jamieson P. A. The central nervous system in childhood leukemia. II. Subacute leukoencephalopathy. Cancer. 1975 Feb;35(2):306–318. doi: 10.1002/1097-0142(197502)35:2<306::aid-cncr2820350203>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  5. Price R. A., Johnson W. W. The central nervous system in childhood leukemia. I. The arachnoid. Cancer. 1973 Mar;31(3):520–533. doi: 10.1002/1097-0142(197303)31:3<520::aid-cncr2820310306>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  6. Rubinstein L. J., Herman M. M., Long T. F., Wilbur J. R. Disseminated necrotizing leukoencephalopathy: a complication of treated central nervous system leukemia and lymphoma. Cancer. 1975 Feb;35(2):291–305. doi: 10.1002/1097-0142(197502)35:2<291::aid-cncr2820350202>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  7. Sullivan M. P., Humphrey G. B., Vietti T. J., Haggard M. E., Lee E. Superiority of conventional intrathecal methotrexate therapy with maintenance over intensive intrathecal methotrexate therapy, unmaintained, or radiotherapy (2000-2500 rads tumor dose) in treatment for meningeal leukemia. Cancer. 1975 Apr;35(4):1066–1073. doi: 10.1002/1097-0142(197504)35:4<1066::aid-cncr2820350408>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  8. Sullivan M. P., Vietti T. J., Fernbach D. J., Griffith K. M., Haddy T. B., Watkins W. L. Clinical investigations in the treatment of meningeal leukemia: radiation therapy regimens vs. conventional intrathecal methotrexate. Blood. 1969 Sep;34(3):301–319. [PubMed] [Google Scholar]
  9. Sullivan M. P., Vietti T. J., Haggard M. E., Donaldson M. H., Krall J. M., Gehan E. A. Remission maintenance therapy for meningeal leukemia: intrathecal methotrexate vs. intravenous bis-nitrosourea. Blood. 1971 Dec;38(6):680–688. [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES